CardioMap® heart monitoring and screening device, will provide early, non-invasive testing of heart disease. With its highly portable design and web-based analysis, it can both penetrate the existing $28B cardiac device market and also expand the market vertical by opening up the possibilities for remote and home screening.
Prevacus Concussion Drug Development
Prevacus, Inc. was formed in June of 2012 in the State of Delaware. Prevacus has been developing two candidates for use in traumatic brain injury (TBI) with a primary focus treating mild TBI (mTBI) a.k.a. concussion.
The Prevacus team has led the development of two nasally administered candidates (PRV-001 and PRV-002) through synthesis and pre-clinical efficacy studies. Both candidates are neurosteroids and easily cross the blood-brain barrier. However, the commercial scalability in the synthetic process is much better in what is now the lead candidate, PRV-002.
Second Chance Choking Rescue device
The Second Chance is organized to introduce to the medical device industry a revolutionary, patented, easy to use choking rescue device.
Choking is the obstruction of the flow of air from the environment into the lungs. Choking prevents breathing. Partial choking allowing some, although inadequate, flow of air into the lungs while complete allows no airflow. Prolonged or complete choking, results in asphyxia which leads to anoxia and is potentially fatal.